Selected transactions

Exclusive Financial Advisor to Mesotherapy leader Suisselle in the structuring of the strategic partnership for the licensing of their novel skinbooster “Cellbooster” to Chinese partner Sihuan Pharmaceuticals.

Exclusive Financial Advisor to Bloomage for the completion of a strategic partnership including the investment in a minority equity ownership and entry into a long- term licensing agreement.

Exclusive Financial Advisor to Bloomage for the payment structure aligned with future financial performance.

Exclusive Financial Advisor to Bloomage for the completion of a strategic partnership and investment of 33.4% in Laboratoires Vivacy.

Exclusive Financial Advisor to Institut Mérieux’s in the divestiture of a 78% majority stake in the Indian Prophylactic vaccine company Shantha Biotechnics to Sanofi-Aventis.

Divestiture of Toride (near Tokyo) facility, Boehringer Ingelheim dedicated plant for the manufacturing of ampoules, to HauptPharma AG, Berlin and concurrent entry into a long-term toll manufacturing agreement.

Divestiture of Toyama facility, Boehringer Ingelheim’s dedicated plant for the manufacturing of lyophilized solutions to Yamanouchi-Fujisawa (now Astellas) and concurrent entry into a long-term toll manufacturing agreement via carve-out (“Bunkatsu procedure”).

Completed divestiture of Boehringer Ingelheim’s and SSP’s portfolio of Korean and Japanese subsidiaries.

Completed divestiture via carve-out of Nippon Boehringer Ingelheim’s prescription generics business in Japan (Total sales €100m in 2003) including a guarantee payment by Boehringer Ingelheim for a 2 Year post-closing employment continuation.